Dendrite UK announces Infonetica deal

30 October 2006

Dendrite UK says it is now able to offer its customers even more comprehensive data on the structure, operation and reform of the UK National Health Service. The result of an agreement with Infonetica provides full access to its National Health Intelligence Service (NHIS) database to Dendrite clients. When combined with Dendrite's own Customer Database Management Service, PharbaseSM, this will provide an information source and library facility containing unsurpassed levels of information, the firm claims.

NHIS offers a range of in-depth information on the changing NHS including all the 2006 quality and outcomes framework, disease prevalence, practice-based commissioning intelligence, as well as financial and health episode statistics in a single location, with structured access and full documentation thereby saving time and effort for the client, says Dendrite.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight